Drug intelligence / Profile preview

PUMCH-E101

Development stage: Phase 1
Lead developer: Peking Union Medical College Hospital
Modality: AAV Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies
Administration: Intravitreal

Overview

PUMCH-E101 is an investigational gene therapy based on adeno-associated virus (AAV) technology, designed for the treatment of inherited retinal diseases caused by mutations in the RDH12 gene. The therapy involves a single intravitreal injection intended to deliver a functional copy of the RDH12 gene to retinal cells, aiming to restore or preserve vision in affected individuals. The drug is being developed and trialed by Peking Union Medical College Hospital, with clinical studies currently focused on patients with RDH12 retinopathy—a form of inherited retinal degeneration that leads to progressive vision loss. Early-phase clinical trials are ongoing to evaluate its safety and preliminary efficacy[6][8][10].

Targets

RDH12 (Retinol dehydrogenase 12)

Beyond the preview

Go deeper on PUMCH-E101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PUMCH-E101.